EL7.AI
StocksMedium•16 November 2026•
3 min read

FDA Rejects Ivonescimab Application Despite Overall Survival Hazard Ratio of 0.76

Key Facts

1Summit announced on November 15, 2026, that it had received a complete response letter concerning its application for ivonescimab.
2Median progression-free survival was 6.8 months with ivonescimab, compared with 4.4 months in the comparator group, with a hazard ratio of 0.52.
3The overall survival hazard ratio was 0.76 in a later analysis with longer follow-up.
4The FDA set November 14, 2026, as the target action date for the application.
5Summit shares closed at $17.84 on November 9 and $14.15 on November 13, 2026.

Summit Therapeutics said on November 15, 2026, that the U.S. Food and Drug Administration had issued a complete response letter for its application for ivonescimab with platinum-containing chemotherapy. The application covers patients with advanced or metastatic non-small cell lung cancer who had previously received EGFR inhibitors. The company said the agency concluded that the application could not be approved in its current form. The agency cited the absence of substantial evidence of effectiveness, given the lack of a statistically significant improvement in overall survival. According to the company's account of the agency's position, an improvement in progression-free survival alone was not sufficient to support a favorable benefit-risk balance.

The application was based on results from HARMONi, a global, randomized, double-blind Phase III trial. The trial compared ivonescimab with platinum-containing chemotherapy against placebo with the same chemotherapy. It enrolled patients with EGFR-mutated non-squamous lung cancer who had previously been treated with a third-generation inhibitor. Summit said the trial met its primary endpoint of progression-free survival. It described HARMONi as the first global Phase III study of an immunotherapy-based regimen to show a statistically significant improvement in this measure in this setting.

Results published in September 2026 showed median progression-free survival of 6.8 months with ivonescimab and chemotherapy, compared with 4.4 months with placebo and chemotherapy. The hazard ratio for the comparison was 0.52. But the endpoint that weighed in the agency's decision was overall survival, not progression-free survival alone. In the primary overall survival analysis, the treatment showed a positive trend but did not reach statistical significance. As a result, the progression-free survival finding did not offset the absence of statistical significance in overall survival, according to the rationale for the decision cited by the company.

Summit pointed to a later analysis with longer follow-up, in which the overall survival hazard ratio was 0.76 in the full study population, as well as among Asian and Western patients. The company presented this result as evidence that the survival benefit was consistent across regions. However, the disclosure describes it as a later analysis, while stating that the primary analysis did not achieve statistical significance. This distinction separates the trial's result on the progression-free survival measure from the basis on which the company said the agency rejected the application. The application had been accepted in January, and the agency set November 14, 2026, as its target action date.

Summit shares closed at $17.84 on November 9 and $14.15 on November 13, 2026, according to EL7 data. The latest close was from a session before the company's November 15 announcement, so it does not represent a reaction to the complete response letter news. The available data did not include a price after the announcement. This sequence provides context for the stock's movement before the news, without attributing it to the regulatory decision. The confirmed event on the later date was Summit's announcement that it had received the letter concerning its application.

Chairman and co-CEO Robert Duggan said the company would continue developing ivonescimab, citing five positive Phase III studies between Summit and its partner Akeso. He added: "With five positive Phase III studies between Summit and Akeso, nothing changes in our growing conviction in the opportunities for ivonescimab." In the broader context of the drug, the company says it received its first marketing approval in China in May 2024. It also says there are currently no approved bispecific antibodies targeting PD-1 and VEGF in the United States. This means the development path the company is pursuing extends beyond the rejected U.S. application, while the agency's decision concerns the specific use examined in HARMONi.

Open on chart